Accuray Inc

Accuray’s steep stock decline and negative earnings highlight critical financial volatility, yet the company’s radiation‑oncology R&D could reshape its future in the competitive health‑care equipment sector.

Accuray Inc. reported a mixed fiscal 2025 performance, with a quarterly revenue dip but a record annual revenue of $458.5 million, driven by its radiation oncology systems and global tumor treatment solutions.